Brief: Gland Pharma Says US FDA Conducted Good Manufacturing Practice Inspection at Co's VSEZ Sterile Oncology Facility
28/07/2023 12:17
July 28 (Reuters) - Gland Pharma Ltd GLAD.NS :
* INSPECTION WAS CONCLUDED WITH ZERO 483 OBSERVATIONS
* US FDA CONDUCTED GOOD MANUFACTURING PRACTICE INSPECTION
AT CO'S
VSEZ STERILE ONCOLOGY FACILITY AT VISAKHAPATNAM
* CONCLUDED WITH ZERO 483 OBSERVATIONS AND A CLASSIFICATION
OF NO
ACTION INDICATED
Source text for Eikon: ID:nBSE3J3LBk
Further company coverage: GLAD.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gland Pharma
See all newsIndia Stocks: Indian shares open higher as Fed-hike fears, oil prices ease; financials lead
India Stocks: Indian shares poised to rebound as Fed-hike fears, oil prices ease
Brief: Gland Pharma Approves $21 Million Investment In Gland Pharma Usa
Brief: Fosun Pharma Says Unit Sold Gland Pharma Shares for $294 Mln
India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant